Halladay Benjamin sold (to issuer) 705,410 shares of ESPR
Halladay Benjamin (Chief Financial Officer) sold (to issuer) 705,410 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s sale of 705,410 shares to the issuer on 2026-07-13, leaving the insider with 0 shares; no price or total value is provided.
Market read
Traders may monitor ESPR for sentiment effects from senior insider selling, but the filing provides no fundamental update.
What to watch
No 10b5-1 plan is stated, but the transaction code D (sale to issuer) and lack of price/value make it hard to infer intent or magnitude versus typical insider activity.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc.
Ticker impact
Esperion CFO Halladay Benjamin sold 705,410 shares to the issuer on 2026-07-13, with price undisclosed and holdings reduced to zero.
Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.
The filing is a primary-source Form 4, but the transaction details lack price and do not indicate a new operating or regulatory catalyst. Insider sales are common and often pre-arranged, and the filing explicitly notes no 10b5-1 plan.
Market effects
Minimal, as this is company-specific insider transaction data without sector-wide signal.
None indicated.
None indicated.
Counterpoint
The sale is to the issuer and may reflect liquidity management or plan mechanics rather than bearish fundamentals, especially with no disclosed price or stated rationale.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHalladay Benjamin
Esperion CFO who sold 705,410 shares to the issuer on 2026-07-13.